Oral drug blocks SARS-CoV-2 transmission in ferrets, researchers find
Posted: 4 December 2020 | Victoria Rees (Drug Target Review) | No comments yet
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
A team has developed a new potential antiviral drug to combat infection from SARS-CoV-2, the virus causing the COVID-19 pandemic. Named Molnupiravir (MK-4482/EIDD-2801), the molecule was originally developed by Emory University, US, and was licensed by Ridgeback Biotherapeutics for development, in collaboration with Merck.
The study was conducted at the Institute for Biomedical Sciences at Georgia State University, US. The group, led by Dr Richard Plemper, originally discovered that the drug is potent against influenza viruses and completely suppresses virus transmission within 24 hours.
Early on, the researchers noted that MK-4482/EIDD-2801 has broad-spectrum activity against respiratory RNA viruses and that treating infected animals by mouth with the drug lowers the amount of shed viral particles by several orders of magnitude, dramatically reducing transmission. This led them to suggest it could be used to prevent the transmission of SARS-CoV-2.
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing
This report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
Inside the report:
- Advance discovery through miniaturised, high-throughput and animal-free systems
- Integrate AI, robotics and analytics to speed decision-making
- Streamline cell therapy and bioprocess QC for scale and compliance
- And more!
This report unlocks perspectives that show how automation is changing the scale and quality of discovery. The result is faster insight, stronger data and better science – access your free copy today
The team repurposed MK-4482/EIDD-2801 against SARS-CoV-2 and used a ferret model to test the effect of the drug on halting virus spread.
“We believe ferrets are a relevant transmission model because they readily spread SARS-CoV-2, but mostly do not develop severe disease, which closely resembles SARS-CoV-2 spread in young adults,” said Dr Robert Cox, co-lead author of the study.
The researchers infected ferrets with SARS-CoV-2 and initiated treatment with MK-4482/EIDD-2801 when the animals started to shed virus from the nose.
“When we co-housed those infected and then treated source animals with untreated contact ferrets in the same cage, none of the contacts became infected,” said Josef Wolf, a doctoral student and co-lead author of the study. By comparison, the researchers found that all contacts of source ferrets that had received placebo became infected.
The team say if these ferret-based data translate to humans, COVID-19 patients treated with the drug could become non-infectious within 24 hours after the beginning of treatment.
“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission,” said Plemper. “MK-4482/EIDD-2801 could be game-changing.”
Ridgeback and Merck are currently conducting Phase II/III clinical trials of molnupiravir.
The study was published in Nature Microbiology.
Related topics
Drug Development, Drug Leads, Drug Targets, In Vivo, Lead Generation, Research & Development, Target Validation, Targets, Therapeutics
Related conditions
Covid-19
Related organisations
Georgia State University, Merck, Ridgeback Biotherapeutics
Related people
Dr Richard Plemper, Dr Robert Cox, Josef Wolf
